semaglutide prediabetes weight loss trial progression to diabetes Efficacy and safety of once-weekly 2·4 GLP-1 Receptor Agonists as Treatments

This distinction matters in the GLP-1 market, as regulatory scrutiny, quality controls, and allowable production practices vary significantly between the two models and, as of April 2026, the two tiers face meaningfully different enforcement exposure

Furthermore, the long-term safety of such a combination is entirely unknown

Results can last as long as the patient maintains the lifestyle changes and follows medical advice

Compounded versions include semaglutide and tirzepatide

That work has previously attracted endorsement from Professor Windy Dryden , a leading figure in CBT, and Professor Philip Zimbardo , the Stanford psychologist known for his work on time perspective